McKesson’s (MCK) More Powerful Than President Trump, Says Jim Cramer

Core Viewpoint - McKesson Corporation (NYSE:MCK) is highlighted as a significant player in the healthcare services sector, with strong stock performance and positive analyst outlooks, despite some market challenges [2][3]. Company Performance - McKesson's shares have increased by 59% over the past year and by 15% year-to-date [2]. - TD Cowen raised the share price target to $1,012 from $1,000 while maintaining a Buy rating, citing strong performance in the pharmaceutical and cancer businesses [2]. - Morgan Stanley also raised its price target to $966 from $916, keeping an Overweight rating, with optimism driven by the cancer business [2]. Market Context - The company is noted for its significant role in the healthcare industry, being one of the largest providers in America [2]. - Jim Cramer has recently discussed McKesson in the context of its influence and market position, even comparing its power to that of President Trump [3].